NCT01094067

Tezosentan in Patients With Pulmonary Arterial Hypertension

Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	ACT-050089	5 mg/h intravenously, Tezosentan
OTHER	Placebo	Matching placebo

Timeline

• Start date: 2010-09-01
• Primary completion: 2010-12-01
• Completion: 2011-09-01
• First posted: 2010-03-26
• Last updated: 2018-07-09

Locations

5 sites across 3 countries: United States, France, Japan